Investor Center

Company Overview

Radnostix is a U.S.-based manufacturer and global supplier of nuclear medicine products, medical devices, and calibration standards with a nearly three-decade track record of innovation and reliability. Established in 1995 and headquartered in Idaho Falls, Idaho, the company has built a reputation as a trusted partner for hospitals, radiopharmacies, imaging centers, and research institutions worldwide.

Radnostix operates at the intersection of theranostics, nuclear medicine, industrial isotope applications, and radiation safety, addressing growing global demand for diagnostic imaging, targeted cancer therapies, and dependable calibration and shielding solutions. With a vertically integrated manufacturing platform and state-of-the-art facilities in Idaho Falls, Radnostix is uniquely positioned as one of the few companies in the United States capable of producing both radiopharmaceuticals and sealed source isotopes under FDA and ISO-certified quality systems.

The company’s portfolio spans several synergistic business units: radiopharmaceutical products such as sodium iodide I-131, used in the diagnosis and treatment of thyroid disease; RadQual calibration standards and reference sources, relied upon by nuclear pharmacies and imaging centers to ensure precise and accurate measurements; Cobalt-60 sealed sources used in cancer therapy and industrial sterilization; innovative medical devices like the Swirler® and Tru-Fit™ mouthpieces introduced under its RadVent division; and advanced synthesis modules and shielding products delivered through strategic distribution and joint venture partnerships.

Over the last several years, Radnostix has also executed a deliberate strategy of expansion and diversification. This includes the acquisition of AMICI, Inc.’s Xenon System and related product lines, the launch of joint ventures like PhanQual for sealed-source phantom calibration, and exclusive distribution agreements for Scintomics/ATT radiosynthesis modules and Nuclear Shields radiation protection products. These initiatives not only strengthen Radnostix’s portfolio but also expand its footprint across key global markets, including North America, Europe, Latin America, and Asia.

As the demand for nuclear medicine and theranostics continues to accelerate, Radnostix is committed to leveraging its specialized expertise, expanding product lines, and maintaining strict quality standards to deliver sustained growth and long-term value for its shareholders. The company’s consistent revenue growth, improving profitability metrics, and strategic positioning make INIS a compelling investment opportunity in one of the fastest-growing sectors of healthcare and advanced materials.

The Radnostix Family of Brands